Last reviewed · How we verify
NCT05581550
Somatostatin Receptor Imaging in NPC, EBV Related Cancers
NA trial testing FDG-PET in Nasopharyngeal Cancer in 15 participants. Completed in 17 July 2025.
17 July 2025
Quick facts
| Lead sponsor | National Cancer Centre, Singapore |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 15 |
| Start date | 29 June 2020 |
| Primary completion | 17 July 2025 |
| Estimated completion | 17 July 2025 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- FDG-PET — full drug profile →
- Galium-68 DOTATATE
Conditions studied
- Nasopharyngeal Cancer — all drugs for Nasopharyngeal Cancer →
- Epstein-Barr Virus Related Carcinoma — all drugs for Epstein-Barr Virus Related Carcinoma →
Sponsor
National Cancer Centre, Singapore
Who can join
21 and older, any sex, with Nasopharyngeal Cancer or Epstein-Barr Virus Related Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A case of metastatic lymphoepithelial carcinoma of parotid gland identified on <sup>68</sup>gallium DOTA-[Tyr3] octreotate PET CT.
Low HC, Loke KSH, Wang FQ, Han S, et al · · 2024 · PMID 38352266 · DOI 10.1093/bjrcr/uaad011
Verify or expand the search:
- PubMed search for NCT05581550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of FDG-PET
Trials testing the same drug.
- NCT06797661 — Insights Into the Pathophysiology of Neurovascular Uncoupling in Patients with Brain Lesions. · NA · recruiting
- NCT06648317 — Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions · recruiting
- NCT06167603 — Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision · unknown
- NCT06019975 — FDG-PET in the Diagnosis of Autoimmune Encephalitis · recruiting
- NCT06833229 — Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or · recruiting
Other recruiting trials for Nasopharyngeal Cancer
Currently open trials in the same condition.
- NCT06749899 — QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. · Phase 3 · recruiting
- NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting
- NCT06349889 — Adebrelimab and Chemoradiotherapy in High-risk LANPC · Phase 2 · recruiting
- NCT06414577 — Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Af · Phase 2 · active not recruiting
- NCT05983432 — Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · Phase 1 · recruiting
Other National Cancer Centre, Singapore trials
Trials by the same sponsor.
- NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
- NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
- NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
- NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
- NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05581550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
- Last refreshed: 20 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05581550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing